UBS Maintains Buy on Solventum, Raises Price Target to $101
UBS analyst Kevin Caliendo maintains Solventum (NYSE:SOLV) with a Buy and raises the price target from $95 to $101.
Read original at benzingaStocks · News reference
Solventum Plans To Separate Its Health Information Systems Operations As Part Of Its Portfolio Optimization Strategy
Solventum (NYSE: SOLV) today announced its intention to pursue a separation of its Health Information Systems business as part of the company's ongoing portfolio optimization strategy. The company will evaluate a
Reference details
Connected markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Aug 5, 2026, 8:53 PM
- Checked
- Aug 5, 2026, 8:53 PM
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related headlines
Solventum shares are trading lower after the company reported Q2 financial results. The stock initially rallied yesterday after the market closed, but it has since reversed.
Read original at benzingaPiper Sandler Maintains Overweight on Solventum, Raises Price Target to $105
Piper Sandler analyst Jason Bednar maintains Solventum (NYSE:SOLV) with a Overweight and raises the price target from $92 to $105.
Read original at benzingaWedbush Maintains Outperform on Solventum, Raises Price Target to $101
Wedbush analyst Michael Piccolo maintains Solventum (NYSE:SOLV) with a Outperform and raises the price target from $94 to $101.
Read original at benzinga